Heredity

Bucknell University and Lycoming College collaborate to present bestselling author talks

Retrieved on: 
星期三, 二月 15, 2023
Human, Sports on Amazon Prime Video, Lycoming, Science, Bucknell, Woman, Muncy, Lycoming College, Anthropology, Q&A, Heredity, Psychology, Publication, The Good House, NPR, Eugenics, Research, Genetics, Foundling, Intellectual, Parent, History, College, Good, Politics, Sociology, BYU College of Family, Home and Social Sciences, Real Simple, George W. and Sarah Trogner House, Multimedia, Bucknell University, Modern Love, Poetry, Ageing, Nursing, Publishing, Redbook, The New York Times

Bucknell will host Leary on Tuesday, March 7, at 7 p.m., in Bucknell Hall.

Key Points: 
  • Bucknell will host Leary on Tuesday, March 7, at 7 p.m., in Bucknell Hall.
  • Lycoming will host her on Wednesday, March 8, at 7 p.m., in the Trogner Presentation Room in the Krapf Gateway Center.
  • New York Times bestselling author Ann Leary will lecture at both Bucknell University and Lycoming College in March.
  • Leary is the New York Times bestselling author of a memoir and four novels including The Good House.

GENE to Launch World’s First Comprehensive Risk Test for Breast & Ovarian Cancer

Retrieved on: 
星期五, 二月 3, 2023
Health, Breast cancer, Family, ASX, Consumer, Genetypes, Classification, Cancer, BRCA, Hereditary breast–ovarian cancer syndrome, Risk, Survival, Heredity, Ovarian cancer, HBOC, Risk assessment, GTG, Woman, Business-to-business, Birth control, Breast

Combined with other clinical risk factors the test provides a comprehensive risk assessment in a simple saliva test.

Key Points: 
  • Combined with other clinical risk factors the test provides a comprehensive risk assessment in a simple saliva test.
  • New test integrates the patented and proprietary GeneType platform for both Breast and Ovarian Cancer.
  • GTG’s unique approach “appends” the detection of the 13 major “actionable” breast and ovarian cancer susceptibility genes to the GeneType test platform.
  • Our non-invasive risk assessment test will address cancer risk at a population health level.”
    Authorised for release by the board of directors of Genetic Technologies Limited.

Genetic Technologies Presented Improved Clinical Colorectal Cancer Risk Prediction Model Integrating Polygenic Risk at ASCOGI Cancer Symposium

Retrieved on: 
星期二, 一月 24, 2023
Health, Disease, Society, Large intestine, ASX, Genetypes, Poster, Marker beacon, Social and Behavioral Sciences Team, Colorectal cancer, Cancer, Single-nucleotide polymorphism, Risk, Bureau of Oceans and International Environmental and Scientific Affairs, Heredity, Patient, Risk assessment, SNP, GTG, Vaccine, Dietary supplement

The Poster titled “Improvement of a clinical colorectal cancer risk prediction model integrating polygenic risk” was authored by GTG’s Science Team including Erika Spaeth, Aviv Gafni, Richard Allman and Gillian Dite.

Key Points: 
  • The Poster titled “Improvement of a clinical colorectal cancer risk prediction model integrating polygenic risk” was authored by GTG’s Science Team including Erika Spaeth, Aviv Gafni, Richard Allman and Gillian Dite.
  • The poster demonstrates improved performance, identifying patients at risk of developing colorectal cancer by expanding number of SNPs from 45 to 144.
  • The patients in the top risk category showed a 27% improvement compared with the 45 SNP geneType model.
  • GTG’s geneType Risk Assessment test is directly targeting this population to enable the early identification of colorectal cancer.

United States Hereditary Genetic Testing Market Analysis and Forecasts, 2022-2032 with Laboratory Corporation of America Holdings, Quest Diagnostics, & F. Hoffmann-La Roche Dominating - ResearchAndMarkets.com

Retrieved on: 
星期一, 一月 9, 2023
Health, Genetics, Genetic testing, LabCorp, Parkinson's disease, Heredity, Brain, Ascension, Benchmarking, Illumina, Inc., LRRK2, Epidemiology, Partnership, Genetic, Growth, Qiagen, Drug discovery, Prevalence, Software, Research, Cancer, Agriculture, Pharmaceutical industry, Vaccine, Audit, Medical imaging

Hereditary Genetic Testing Market: Focus on Product, Sample Type, Application Area, and Genetic Testing Type - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • Hereditary Genetic Testing Market: Focus on Product, Sample Type, Application Area, and Genetic Testing Type - Analysis and Forecast, 2022-2032" report has been added to ResearchAndMarkets.com's offering.
  • Among application area, all the four sub-segments constitute an almost equal share in the U.S. hereditary genetic testing market.
  • Hereditary Genetic Testing Market
    On 3 October 2022, Laboratory Corporation of America Holdings concluded the transactions, establishing a long-term laboratory connection with Ascension.
  • The following companies had a total market share of over 25% in 2021 and were highly active in the U.S. hereditary genetic testing market:

Alterity Therapeutics Announces Allowance of New Composition of Matter Patent by the United States Patent and Trademark Office

Retrieved on: 
星期四, 十二月 29, 2022
Dementia, Protein, PMID, Iron, United States Patent and Trademark Office, DOI, Central nervous system, Pathology, Lisa Ng, Thought, Atrophy, Infection, SAN, Dopamine, Brain, Drug discovery, Social skills, Tremor, Parkinson's disease, Disease, Patent, Alzheimer's disease, Heredity, Biomarker, ISSN, ATH, Malnutrition, Rigidity, Shamsi Fazlollahi, Neurodegeneration, Multimedia, Fatigue, Constipation, ASX, Ageing, Therapy, Dehydration, S, Genetics, Pharmaceutical industry, Medical imaging, Vaccine, PD, Neuroscience, Parkinsonism, Alterity

MELBOURNE, Australia and SAN FRANCISCO, Dec. 29, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that a new composition of matter patent has been allowed by the United States Patent and Trademark Office (USPTO). The patent was allowed following expedited review by the USPTO. 

Key Points: 
  • Importantly, the patent covers iron chaperones which are small molecules capable of binding and redistributing excess iron in the central nervous system.
  • "This patent strengthens our portfolio of compounds for treating important neurodegenerative diseases such as Parkinson's and Alzheimer's," said David Stamler, M.D., Chief Executive Officer, Alterity.
  • "With this patent, our discovery team has created a new scaffold that extends our approach of targeting key proteins implicated in these diseases.
  • Progress in Neurobiology, Volume 155, 2017, Pages 96-119, ISSN 0301-0082, https://doi.org/10.1016/j.pneurobio.2015.09.012
    This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

CMS (867.HK) Joins Hand with Incyte on Ruxolitinib Cream, Brings 1st Repigmentation Drug for Vitiligo Patient

Retrieved on: 
星期二, 十二月 6, 2022
Cream, Janus, Woman, JAK, Sclerotherapy, Quality of life, AD, Incidence, Partnership, Atopic dermatitis, Heredity, Autoimmune disease, Marketing, FDA, Safety, Vitiligo, CMS, Skin, Tablet, Dermatology, PD-1, Neck, TCS, Face, Plasma protein binding, Territory, Conditional sentence, Patient, Report, Alopecia areata, Prejudice, Varicose veins, Disease, Ruxolitinib, Patent, FGFR1, Janus kinase 1, Week, TCI, Pharmaceutical industry, Fine chemical, Lancet, Incyte, Novartis, Lilly

Ruxolitinib Cream is the only topical JAK inhibitor and the first vitiligo repigmentation drug approved by the U.S. FDA.

Key Points: 
  • Ruxolitinib Cream is the only topical JAK inhibitor and the first vitiligo repigmentation drug approved by the U.S. FDA.
  • Through this transaction, CMS once again brings a novel treatment option for patients with unmet medical needs.
  • The product was approved by the FDA in July 2022 for the topical non-segmental vitiligo patients.
  • In July this year, Ruxolitinib Cream became the first and only drug approved by the U.S. FDA for vitiligo patients repigmentation.

Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference

Retrieved on: 
星期二, 十二月 6, 2022
Conference, Psychopharmacology, Sporadic group, Life expectancy, Multiple sclerosis, Behavior, Diagnosis, Noonan syndrome, Motor neuron, CNS, Chemistry, Heredity, National academy, Amyotrophy, ALS, FDA, Biotechnology, Death, Amyotrophic lateral sclerosis, Central nervous system, Spinal cord, Antibody, MIAMI, Alpha-5 beta-1, Neuroscience, Survival, KTTA, SOD1, Research, Neurodegeneration, Therapy, Integrin, Brain, Patient, Pharmaceutical industry

Pasithea’s discovery candidate, PAS-003, has a novel mechanism of action with the potential to improve clinical outcomes in patients with ALS.

Key Points: 
  • Pasithea’s discovery candidate, PAS-003, has a novel mechanism of action with the potential to improve clinical outcomes in patients with ALS.
  • “We’re pleased to present our data at such a prestigious annual conference that includes a keynote address by this year’s Nobel Laureate for chemistry,” commented Dr. Steinman.
  • Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders.
  • PAS-003 is monoclonal antibody targeting alpha5/beta1 integrin for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurological diseases.

Arthrex Launches BunionPain.com to Educate Patients on Bunion Treatment Options

Retrieved on: 
星期一, 十二月 5, 2022
Trauma, Ankle, Heredity, Bunion, Woman, PECA, Deformity, Spine, Quality, Patient, Science, Ford Motor Company, Pain, Multimedia, Education, OR, Arthroplasty, Institute for Quality and Efficiency in Health Care, Elective surgery, Schuberth, Foot, Medical device, Dentistry, Extremities

NAPLES, Fla., Dec. 5, 2022 /PRNewswire/ -- Arthrex, a global leader in minimally invasive orthopedic technology, launched BunionPain.com, the company's patient-focused website, focused on Arthrex's innovative procedure for minimally invasive bunion correction.

Key Points: 
  • Website focuses on patient education about causes, treatment with the Arthrex Minimally Invasive Bunionectomy
    NAPLES, Fla., Dec. 5, 2022 /PRNewswire/ --Arthrex, a global leader in minimally invasive orthopedic technology, launched BunionPain.com , the company's patient-focused website, focused on Arthrex's innovative procedure for minimally invasive bunion correction.
  • Our goal with BunionPain.com is to create an educational hub for those seeking information about the science of bunions, their potential treatment options and how they can connect with expert surgeons in their area," said Arthrex Senior Director of Extremities and Trauma Pete Denove.
  • Bunions, which can be hereditary or caused by footwear, affect an estimated 30% to 50% of Americans.
  • Lee M, Walsh J, Smith MM, Ling J, Wines A, Lam P.Hallux valgus correction comparing percutaneous chron/Akin (PECA) and open scarf/Akin osteotomies.Foot Ankle Int.

bit.bio Expands Its Portfolio With Three New Human Cell Products for Research and Drug Discovery in Neurodegenerative and Neurological Diseases

Retrieved on: 
星期三, 十一月 23, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, FTD, Patient, Frontotemporal dementia, Language, Foresite Capital, Neuron, Tau, IPSC, Brain, Hyperphosphorylation, Cell, Pathology, Series, Avenue, Autism, Potency (pharmacology), University, Epilepsy, Machine learning, Alzheimer's disease, Transplant, Multimedia, Aggregation, CNS, Research, CRISPR, HIV disease progression rates, Charles River Laboratories, Disease, Biology, GABAergic, Therapy, Memory, Stanford University, SAB, Nobel Prize in Physiology or Medicine, Heredity, Drug discovery, Schizophrenia, Personality, Synthetic biology, Roivant Sciences, Nobel Prize, Atrophy, MAPT, Aroma compound, Fine chemical, Pharmaceutical industry, Vaccine, Medical imaging, Medical device, Tencent, Medicine

bit.bios cell products are reprogrammed from human induced pluripotent stem cells (hiPSCs) using the companys proprietary precision reprogramming technology opti-oxTM.

Key Points: 
  • bit.bios cell products are reprogrammed from human induced pluripotent stem cells (hiPSCs) using the companys proprietary precision reprogramming technology opti-oxTM.
  • These key features make the products ideally suited to screening applications for early drug discovery as well as for fundamental research.
  • Dr Farah Patell-Socha, VP Research Products at bit.bio, said:
    The launch of these products is further evidence of our robust CNS cell pipeline for research and drug discovery.
  • bit.bio is a synthetic biology company providing human cells for research, drug discovery and cell therapy.

Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy

Retrieved on: 
星期一, 十一月 21, 2022
Automotive, Women, Other Science, Seniors, FDA, Research, Managed Care, Men, Family, Consumer, General Automotive, Pharmaceutical, Oncology, Mental Health, Hospitals, Clinical Trials, Cardiology, Biotechnology, Health, Science, Novo Nordisk, Neurodegeneration, Partnership, Amyloidosis, ATTR, TTR, Amyloid, Research, Safety, Security (finance), Acquisition, Mortality, Biology, AL, Therapy, Heredity, Patient, Pharmaceutical industry

There remains a high unmet medical need in moderate to advanced ATTR amyloidosis patients at high risk for early mortality due to amyloid deposition in vital organs.

Key Points: 
  • There remains a high unmet medical need in moderate to advanced ATTR amyloidosis patients at high risk for early mortality due to amyloid deposition in vital organs.
  • Under the terms of the agreement, Prothena is eligible to receive up to $1.2 billion dollars upon achievement of several clinical development and sales milestones, including the $100 million earned to date.
  • Novo Nordisk gained full worldwide rights to the intellectual property and related rights of the ATTR amyloidosis business and pipeline it acquired from Prothena in July 2021.
  • The 52-week trial is investigating safety and efficacy of NNC6019 in 99 people with transthyretin amyloid cardiomyopathy.